Sign In
Buy PODD
$143.30
+0.87 (+0.611%)
At Close: Jun 03, 2026
Why Shares of Insulet Dropped This Week
05:40pm, Thursday, 12'th Oct 2023
Insulet makes a tubeless insulin pump. The company is coming off a strong second quarter.
Insulet (PODD) Loses -24.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:17am, Thursday, 12'th Oct 2023
Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e
5 Medical Product Stocks to Buy Amid Industry Recovery
09:46am, Thursday, 12'th Oct 2023
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-pois
What other industries could weight loss drugs disrupt?
07:10pm, Wednesday, 11'th Oct 2023
Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.
Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?
01:32pm, Wednesday, 11'th Oct 2023
Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Down -17.48% in 4 Weeks, Here's Why Insulet (PODD) Looks Ripe for a Turnaround
11:18am, Tuesday, 10'th Oct 2023
The heavy selling pressure might have exhausted for Insulet (PODD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Why
02:17pm, Monday, 09'th Oct 2023
Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Looking for Earnings Beat? 5 Top-Ranked Stocks to Play
08:16am, Monday, 09'th Oct 2023
These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap NVIDIA (NVDA), Lamb Weston (LW), Insulet (PODD), Asure Software (ASUR) and Palo Alto Networks (PANW).
Diabetes-related stocks take hit over weight loss drug craze
01:00pm, Saturday, 07'th Oct 2023
This segment originally aired on October 5, 2023 Weight loss drugs, like Novo Nordisk's (NVO) Ozempic, have become popular across healthcare providers in regard to diabetes treatment. Although use is
Are the S&P 500's Biggest Q3 Losers Next Year's Winners?
09:15am, Wednesday, 04'th Oct 2023
What started out to be a promising third quarter for U.S. stocks turned into a dud. On the backs of artificial intelligence (AI) excitement, the S&P 500 stormed out of the gates in July only to trend
Glucose Game-Changers: 3 Diabetes Stocks to Grab on the Downturn
05:53am, Wednesday, 04'th Oct 2023
In recent months, diabetes stocks have retreated sharply, partly due to the increased popularity of the weight-loss drug Semaglutide. Some have contended that Semaglutide will greatly reduce the numbe
Insulet CFO to step down to join 3M's healthcare business
05:07pm, Tuesday, 03'rd Oct 2023
Insulet Corp said on Tuesday Wayde McMillan would step down as the medical device maker's chief financial officer, effective Oct. 20, to join 3M's healthcare business.
New weight loss drugs could mean a $25 billion drag on restaurants by 2025, says Mizuho's Dan Dolev
02:58pm, Tuesday, 03'rd Oct 2023
Matt Taylor, Jefferies analyst, and Dan Dolev, managing director at Mizuho Securities, join 'The Exchange' to discuss how new weight loss drugs could decline revenue for restaurant transaction platfor
SolarEdge, Insulet, and Dollar General Lead S&P 500 Q3 Losses
04:35pm, Monday, 02'nd Oct 2023
SolarEdge Technologies Inc. (SEDG), Insulet Corp. (PODD), and Dollar General Corp. (DG) were the steepest S&P 500 stock decliners in the third quarter as the index lost 3.65%.
Weight-Loss-Drug Stock Sting May Be Easing for Device Makers
01:59pm, Monday, 02'nd Oct 2023
Wall Street says insulin pump maker Insulet and Tandem Diabetes, as well as glucose-monitor maker DexCom, look ready to rise after pressure from Novo Nordisk's Wegovy and Eli Lilly.
